CPX‐351 (Vyxeos®) can cause severe rash in acute myeloid leukemia—A case report

CPX‐351 (Vyxeos®) can cause severe rash in acute myeloid leukemia—A case report

Abstract CPX‐351, a promising new agent for patients with treatment‐related and secondary acute myeloid leukemia can lead to a severe whole‐body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.

Bibliographic Details
Main Authors: Ruth M. Urbantat, Valentin Popper, Elisabeth Menschel, Michael Pfeilstöcker, Ernst Forjan, Alexander Nader, Catherine R. Sieghart, Felix Keil, Elisabeth Koller
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Clinical Case Reports
Subjects:
acute myeloid leukemia
CPX‐351
elderly
rash
Online Access:https://doi.org/10.1002/ccr3.3909

Internet

https://doi.org/10.1002/ccr3.3909

Similar Items